Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
life sciences
national blog main
national top stories
9
×
boston blog main
boston top stories
deals
san francisco blog main
san francisco top stories
national
new york blog main
new york top stories
roche
san diego blog main
san diego top stories
boston
boulder/denver blog main
boulder/denver top stories
cancer
celgene
detroit blog main
detroit top stories
gene editing
gene therapy
indiana blog main
indiana top stories
novartis
pfizer
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alexion pharmaceuticals
alnylam pharmaceuticals
biogen
bristol-myers squibb
What
gene
9
×
therapy
medicine
therapeutics
bio
drug
roundup
advanced
approval
crispr
disease
editing
roche
access
alnylam’s
alzheimer’s
beam
becker
benefit
betting
bff
billion
billions
biopharma
capacity
car
cas
caught
causing
cell
companies
conference
consolidation
crude
cutting
deal
deals
despite
devoted
dicerna
Language
unset
Current search:
biotech
×
" national top stories "
×
gene
×
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M